Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Ado-Trastuzumab Emtansine × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 5 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Salivary Gland Neoplasms 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Hemangiosarcoma 1 HER2-positive Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡